GlobeNewswire Inc | Jan 4, 2022 08:00AM EST

January 04, 2022

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences:

H.C. Wainwright BioConnect 2022 Virtual Conference Presentation Date: Monday, January 10, 2022Time: Pre-recorded on-demand presentation available beginning at 7:00 AM ET

2022 B Riley Virtual Oncology ConferenceFireside Chat Live Webcast Date: Thursday, January 27, 2022Time: 10:30 AM ET

The live and on demand webcasts of both presentations will be available on the Company's website at www.vobrbio.com. An archived replay of each webcast will also be available.

About Vor BiopharmaVor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit:www.vorbio.com.

Contacts:

Investors:Chris BrinzeyICR Westwicke +1 339-970-2843chris.brinzey@westwicke.com

Media:Sarah SpencerVice President, Corporate Communications, Vor+1 857-242-6076sspencer@vorbio.com